Seres Therapeutics, Inc. (MCRB) — Analyst outlook / Analyst consensus target is. Based on 18 analyst ratings, the consensus is bullish — 11 Buy, 3 Hold, 4 Sell.
The consensus price target is $1.25, representing a downside of 85.5% from the current price $8.61.
Analysts estimate Earnings Per Share (EPS) of $-2.40 and revenue of $0.03B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.00 vs est $-2.40 (beat +100%). 2025: actual $0.64 vs est $0.26 (beat +143%). Analyst accuracy: 0%.
MCRB Stock — 12-Month Price Forecast
$1.25
▼ -85.48% Downside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for Seres Therapeutics, Inc., the price target is $1.25.
The average price target represents a -85.48% change from the last price of $8.61.
MCRB Analyst Ratings
Buy
Based on 18 analysts giving stock ratings to Seres Therapeutics, Inc. in the past 3 months
EPS Estimates — MCRB
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.00
vs Est –$2.40
▲ 266,665.6% off
2025
Actual $0.64
vs Est $0.26
▲ 58.9% off
Profitability Outlook
Company is profitable but with thin earnings per share. EPS trend is improving.
Revenue Estimates — MCRB
34%
Analyst Accuracy
Inaccurate
1 year compared
Actual vs Estimate
2025
Actual $0.001B
vs Est $0.000B
▲ 66.2% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast significant revenue growth ahead.
